Drugs / PEG-IFN alpha2b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00887081 | Jan 2009 → Dec 2013 | hemoglobinopathy | Azienda Ospedaliera V. Cervello | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01243281 Comparator | Mar 2011 → May 2013 | chronic hepatitis B virus infection | Chulalongkorn University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-IFN alpha-2b | “to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks” NCT01243281 ↗ |
| Known as | Pegylated Interferon Alpha-2b | “Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B” NCT01243281 ↗ |
| Modality | Protein / enzyme biologic | “combination therapy with pegylated interferon and ribavirin” NCT00887081 ↗ |